Key statistics
On Tuesday, Crinetics Pharmaceuticals Inc (CRNX:NSQ) closed at 43.68, -24.68% below its 52-week high of 57.99, set on Jan 05, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 42.45 |
|---|---|
| High | 44.05 |
| Low | 42.17 |
| Bid | 43.68 |
| Offer | 44.50 |
| Previous close | 42.70 |
| Average volume | 1.12m |
|---|---|
| Shares outstanding | 94.89m |
| Free float | 93.01m |
| P/E (TTM) | -- |
| Market cap | 4.05bn USD |
| EPS (TTM) | -4.53 USD |
Data delayed at least 15 minutes, as of Feb 17 2026 21:00 GMT.
More ▼
- Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March
- Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
- Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)
- Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
- Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
- Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia
- Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia
- Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference
- Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)
More ▼
